Leber Congenital Amaurosis Market
Leber Congenital Amaurosis Market - Global Industry Assessment & Forecast
#
Pages:
217
Base Year:
2024
Feb - 2025
Format:
Report Code:
VMR-4139
Segments Covered
By
Treatment Type Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices, Others
-
By
Target Gene RPE65, GUCY2D, AIPL1, RPGRIP1, CEP290, Other Genes
-
By
End User Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings, Others
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2024 |
| Forecast
Years:
|
2025 - 2035 |
 Historical
Years:
|
2019 - 2023 |
 Revenue
2024: |
USD 1.3 Billion |
 Revenue 2035:
|
USD 2.14 Billion |
 Revenue CAGR
(2025 - 2035): |
4.65% |
Fastest Growing Region (2025 -
2035)
|
Asia Pacific |
Largest Region (2024):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Leber Congenital Amaurosis Market Segment Analysis
- Leber Congenital Amaurosis Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Leber Congenital Amaurosis Target Gene Outlook (Revenue, USD Million, 2018 - 2030)
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Leber Congenital Amaurosis End User Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
-
North America Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
-
North America Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- U.S.
- U.S. Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- U.S. Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- U.S. Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- U.S. Leber Congenital Amaurosis Market, by Treatment Type
- Canada
- Canada Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Canada Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Canada Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Canada Leber Congenital Amaurosis Market, by Treatment Type
-
Mexico
- Mexico Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Mexico Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Mexico Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Mexico Leber Congenital Amaurosis Market, by Treatment Type
-
North America Leber Congenital Amaurosis Market, by Treatment Type
- Europe
-
Europe Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
-
Europe Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
-
Europe Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- U. K.
- U.K. Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- U.K. Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- U.K. Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- U.K. Leber Congenital Amaurosis Market, by Treatment Type
- France
- France Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- France Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- France Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- France Leber Congenital Amaurosis Market, by Treatment Type
-
Germany
- Germany Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Germany Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Germany Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Germany Leber Congenital Amaurosis Market, by Treatment Type
-
Italy
- Italy Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Italy Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Italy Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Italy Leber Congenital Amaurosis Market, by Treatment Type
-
Spain
- Spain Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Spain Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Spain Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Spain Leber Congenital Amaurosis Market, by Treatment Type
-
Rest of Europe
- Rest of Europe Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Rest of Europe Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Rest of Europe Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Rest of Europe Leber Congenital Amaurosis Market, by Treatment Type
-
Europe Leber Congenital Amaurosis Market, by Treatment Type
- Asia Pacific
-
Asia Pacific Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
-
Asia Pacific Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
-
Asia Pacific Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- China
- China Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- China Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- China Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- China Leber Congenital Amaurosis Market, by Treatment Type
- Japan
- Japan Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Japan Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Japan Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Japan Leber Congenital Amaurosis Market, by Treatment Type
-
Germany
- Germany Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Germany Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Germany Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Germany Leber Congenital Amaurosis Market, by Treatment Type
-
India
- India Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- India Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- India Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- India Leber Congenital Amaurosis Market, by Treatment Type
-
South Korea
- South Korea Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- South Korea Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- South Korea Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- South Korea Leber Congenital Amaurosis Market, by Treatment Type
-
South East Asia
- South East Asia Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- South East Asia Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- South East Asia Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- South East Asia Leber Congenital Amaurosis Market, by Treatment Type
-
Rest of Asia Pacific
- Rest of Asia Pacific Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Rest of Asia Pacific Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Rest of Asia Pacific Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Rest of Asia Pacific Leber Congenital Amaurosis Market, by Treatment Type
-
Asia Pacific Leber Congenital Amaurosis Market, by Treatment Type
- Latin America
-
Latin America Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
-
Latin America Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
-
Latin America Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Brazil
- Brazil Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Brazil Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Brazil Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Brazil Leber Congenital Amaurosis Market, by Treatment Type
- Argentina
- Argentina Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Argentina Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Argentina Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Argentina Leber Congenital Amaurosis Market, by Treatment Type
-
Rest of Latin America
- Rest of Latin America Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Rest of Latin America Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Rest of Latin America Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Rest of Latin America Leber Congenital Amaurosis Market, by Treatment Type
-
Latin America Leber Congenital Amaurosis Market, by Treatment Type
- Middle East & Africa
-
Middle East & Africa Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
-
Middle East & Africa Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
-
Middle East & Africa Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- GCC Countries
- GCC Countries Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- GCC Countries Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- GCC Countries Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- GCC Countries Leber Congenital Amaurosis Market, by Treatment Type
- South Africa
- South Africa Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- South Africa Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- South Africa Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- South Africa Leber Congenital Amaurosis Market, by Treatment Type
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Leber Congenital Amaurosis Market, by Treatment Type
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- Rest of Middle East & Africa Leber Congenital Amaurosis Market, by Target Gene
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- Rest of Middle East & Africa Leber Congenital Amaurosis Market, by End User
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- Rest of Middle East & Africa Leber Congenital Amaurosis Market, by Treatment Type
-
Middle East & Africa Leber Congenital Amaurosis Market, by Treatment Type
- North America
Vantage Market
Research | 20-Feb-2025
FAQ
Frequently Asked Question
What is the global demand for Leber Congenital Amaurosis in terms of revenue?
-
The global Leber Congenital Amaurosis valued at USD 1.3 Billion in 2024 and is expected to reach USD 2.14 Billion in 2035 growing at a CAGR of 4.65%.
Which are the prominent players in the market?
-
The prominent players in the market are Pfizer, Novartis, AbbVie, Gilead Sciences, Spark Therapeutics, Biogen, Avexis, Horizon Therapeutics, Aerie Pharmaceuticals, Roche, Regeneron Pharmaceuticals, GenSight Biologics, Orphan Biovitrum, Apellis Pharmaceuticals, Regenxbio, Eyenovia, Aldeyra Therapeutics, Ophthotech Corporation, Santen Pharmaceutical, and Astellas Pharma..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 4.65% between 2025 and 2035.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Leber Congenital Amaurosis include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Leber Congenital Amaurosis in 2024.
